Doxazosin improved COVID-19 associated nightmare in a patient with major depressive disorder: a case report with a positive rechallenge.
Int Clin Psychopharmacol
; 36(4): 221-223, 2021 07 01.
Article
in English
| MEDLINE | ID: covidwho-2051818
ABSTRACT
This article reports on the treatment of a patient with nightmares who was treated with doxazosin of an alpha 1-adrenergic antagonists. A 71-year-old Japanese major depressive disorder (MDD) woman experienced nightmares after the coronavirus disease 2019 pandemic. She had nightmares about being chased by a coronavirus and catching the corona virus. After adding doxazosin 1 mg daily in the morning, her nightmares led to remission without side effects. We also had a rechallenge regimen with doxazosin. The nightmares ceased on the second night of the rechallenge and did not return with continued treatment. This case report suggests that doxazosin may be a useful therapeutic option to target nightmares in individuals with MDD.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Doxazosin
/
Depressive Disorder, Major
/
Dreams
/
Adrenergic alpha-1 Receptor Antagonists
/
COVID-19
Type of study:
Case report
Limits:
Aged
/
Female
/
Humans
Language:
English
Journal:
Int Clin Psychopharmacol
Journal subject:
Psychopharmacology
Year:
2021
Document Type:
Article
Affiliation country:
YIC.0000000000000364
Similar
MEDLINE
...
LILACS
LIS